Literature DB >> 9195099

Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin.

R Ridzon1, J Meador, R Maxwell, K Higgins, P Weismuller, I M Onorato.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9195099     DOI： 10.1093/clinids/24.6.1264

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  22 in total

Review 1.  Current medical treatment for tuberculosis.

Authors:  Edward D Chan; Michael D Iseman
Journal:  BMJ       Date:  2002-11-30

2.  Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.

Authors:  Eric Nuermberger; Sandeep Tyagi; Kathy N Williams; Ian Rosenthal; William R Bishai; Jacques H Grosset
Journal:  Am J Respir Crit Care Med       Date:  2005-09-08       Impact factor: 21.405

3.  Drug-resistant tuberculosis: what are the treatment options?

Authors:  Amr S Albanna; Dick Menzies
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

4.  Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.

Authors:  Tianyu Zhang; Si-Yang Li; Kathy N Williams; Koen Andries; Eric L Nuermberger
Journal:  Am J Respir Crit Care Med       Date:  2011-06-09       Impact factor: 21.405

5.  Drug-induced Liver Injury.

Authors:  Stefan David; James P Hamilton
Journal:  US Gastroenterol Hepatol Rev       Date:  2010-01-01

Review 6.  The role of fluoroquinolones in tuberculosis today.

Authors:  S E Berning
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis.

Authors:  Tina Papastavros; Lisa R Dolovich; Anne Holbrook; Lori Whitehead; Mark Loeb
Journal:  CMAJ       Date:  2002-07-23       Impact factor: 8.262

8.  A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases.

Authors:  Hoda A Makhlouf; Ahmed Helmy; Ehab Fawzy; Madiha El-Attar; Hebat Alla G Rashed
Journal:  Hepatol Int       Date:  2008-07-25       Impact factor: 6.047

9.  Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.

Authors:  Zahoor Ahmad; Sandeep Tyagi; Austin Minkowski; Charles A Peloquin; Jacques H Grosset; Eric L Nuermberger
Journal:  Am J Respir Crit Care Med       Date:  2013-07-01       Impact factor: 21.405

10.  Proposed management of childhood tuberculosis in low-incidence countries.

Authors:  Klaus Magdorf; Anne K Detjen
Journal:  Eur J Pediatr       Date:  2008-05-10       Impact factor: 3.183
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.